تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
28.51 US$
+0.78 US$ · +2.81%
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
الإغلاق السابق
28.51 US$
+0.78 US$ · +2.81%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
نطاق اليوم
السعر الحالي 28.51 US$
نطاق 52 أسبوعًا
السعر الحالي 28.51 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
31
مرتفع السعر
المشاعر
64
صعودي
المخاطر
40
مخاطر متوسطة
الزخم
62
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
نطاق اليوم
السعر الحالي 28.51 US$
نطاق 52 أسبوعًا
السعر الحالي 28.51 US$
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
97.80 US$
ارتفاع محتمل بنسبة 243.04%صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI115.05 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
State Street SPDR S&P Biotech ETFXBI96.81 مليون0.98%9.87 مليار USD0.35%153.77 US$+3.00%
Vanguard Morningstar Small-Cap ETFVB83.14 مليون0.04%185.3 مليار USD0.03%289.48 US$+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK47.85 مليون0.10%44.7 مليار USD0.05%344.74 US$+1.22%
Vanguard Extended Market ETFVXF44.28 مليون0.05%95.4 مليار USD0.05%235 US$+0.80%
Schwab U.S. Small-Cap ETFSCHA18.28 مليون0.08%21.82 مليار USD0.03%32.79 US$+0.40%
iShares Russell Mid-Cap ETFIWR13.95 مليون0.02%56.32 مليار USD0.18%109.82 US$+0.87%
Vanguard Health Care ETFVHT11.02 مليون0.05%22 مليار USD0.09%319.01 US$+1.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell Mid-Cap ETFIWRVanguard Health Care ETFVHTالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
